210 related articles for article (PubMed ID: 28667355)
1. Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1).
Yan X; Zhao J; Zhang R
Cancer Chemother Pharmacol; 2017 Aug; 80(2):395-403. PubMed ID: 28667355
[TBL] [Abstract][Full Text] [Related]
2. IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1).
Du J; He Y; Li P; Wu W; Chen Y; Ruan H
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1111-1119. PubMed ID: 29693201
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription.
Ye P; Xing H; Lou F; Wang K; Pan Q; Zhou X; Gong L; Li D
Cancer Chemother Pharmacol; 2016 Mar; 77(3):613-21. PubMed ID: 26846508
[TBL] [Abstract][Full Text] [Related]
4. Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
Cao Z; Liang N; Yang H; Li S
Cell Prolif; 2017 Oct; 50(5):. PubMed ID: 28762597
[TBL] [Abstract][Full Text] [Related]
5. Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism.
Yang J; Zhang K; Song H; Wu M; Li J; Yong Z; Jiang S; Kuang X; Zhang T
Oncotarget; 2016 May; 7(22):32306-17. PubMed ID: 27058759
[TBL] [Abstract][Full Text] [Related]
6. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
[TBL] [Abstract][Full Text] [Related]
7. Curcumin down-regulates visfatin expression and inhibits breast cancer cell invasion.
Kim SR; Park HJ; Bae YH; Ahn SC; Wee HJ; Yun I; Jang HO; Bae MK; Bae SK
Endocrinology; 2012 Feb; 153(2):554-63. PubMed ID: 22186408
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of TMEM45A overcomes multidrug resistance and epithelial-mesenchymal transition in human colorectal cancer cells through inhibition of TGF-β signalling pathway.
Zhu M; Jiang B; Yan D; Wang X; Ge H; Sun Y
Clin Exp Pharmacol Physiol; 2020 Mar; 47(3):503-516. PubMed ID: 31788833
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription.
Cheng M; Cai W; Huang W; Chen Y; Wu Z; Luo P; Yan W
Eur J Pharmacol; 2018 Dec; 840():1-8. PubMed ID: 30273544
[TBL] [Abstract][Full Text] [Related]
10. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells.
Tsang WP; Kwok TT
Oncogene; 2007 Jul; 26(33):4877-81. PubMed ID: 17297456
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol induces AMPK-dependent MDR1 inhibition in colorectal cancer HCT116/L-OHP cells by preventing activation of NF-κB signaling and suppressing cAMP-responsive element transcriptional activity.
Wang Z; Zhang L; Ni Z; Sun J; Gao H; Cheng Z; Xu J; Yin P
Tumour Biol; 2015 Dec; 36(12):9499-510. PubMed ID: 26124005
[TBL] [Abstract][Full Text] [Related]
12. Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
Ogino Y; Sato A; Kawano Y; Aoyama T; Uchiumi F; Tanuma SI
Anticancer Res; 2019 Dec; 39(12):6457-6462. PubMed ID: 31810909
[TBL] [Abstract][Full Text] [Related]
13. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
Long L; Xiang H; Liu J; Zhang Z; Sun L
Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer.
Yuan Z; Liang X; Zhan Y; Wang Z; Xu J; Qiu Y; Wang J; Cao Y; Le VM; Ly HT; Xu J; Li W; Yin P; Xu K
Br J Cancer; 2020 Apr; 122(9):1342-1353. PubMed ID: 32203206
[TBL] [Abstract][Full Text] [Related]
15. miR-27b-3p is Involved in Doxorubicin Resistance of Human Anaplastic Thyroid Cancer Cells via Targeting Peroxisome Proliferator-Activated Receptor Gamma.
Xu Y; Han YF; Ye B; Zhang YL; Dong JD; Zhu SJ; Chen J
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):670-677. PubMed ID: 29924913
[TBL] [Abstract][Full Text] [Related]
16. Targeted inhibition of HDAC8 increases the doxorubicin sensitivity of neuroblastoma cells via up regulation of miR-137.
Zhao G; Wang G; Bai H; Li T; Gong F; Yang H; Wen J; Wang W
Eur J Pharmacol; 2017 May; 802():20-26. PubMed ID: 28223126
[TBL] [Abstract][Full Text] [Related]
17. Visfatin induces stromal cell-derived factor-1 expression by β1 integrin signaling in colorectal cancer cells.
Huang WS; Chen CN; Sze CI; Teng CC
J Cell Physiol; 2013 May; 228(5):1017-24. PubMed ID: 23042611
[TBL] [Abstract][Full Text] [Related]
18. SH3GL1 inhibition reverses multidrug resistance in colorectal cancer cells by downregulation of MDR1/P-glycoprotein via EGFR/ERK/AP-1 pathway.
Guan H; Zhao P; Dai Z; Liu X; Wang X
Tumour Biol; 2016 Sep; 37(9):12153-12160. PubMed ID: 27220321
[TBL] [Abstract][Full Text] [Related]
19. Visfatin promotes the malignancy of human acute myeloid leukemia cells via regulation of IL-17.
Hui Z; Liu Z; He A; Chen Y; Zhang P; Lei B; Yao H; Yu Y; Liang R; Li Z; Zhang W
Eur J Pharmacol; 2019 Jun; 853():103-110. PubMed ID: 30876976
[TBL] [Abstract][Full Text] [Related]
20. Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.
Wang G; Tian W; Liu Y; Ju Y; Shen Y; Zhao S; Zhang B; Li Y
Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):548-554. PubMed ID: 27224551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
